Our Team

Our Leadership Team

Joe Blanchard, M.B.A

President & Chief Executive Officer

Learn more about Mr. Blanchard
Mr. Blanchard has co-founded and been a member of the leadership teams that helped build several life science companies. Before joining the NeurAegis team, Mr. Blanchard co-founded and served as President & Chief Executive Officer at Amorsa Therapeutics. Prior to Amorsa, he co-founded and served as Chief Operating Officer and Chief Business Officer at Aushon BioSystems (acquired by Quanterix in 2018). Mr. Blanchard was also an early member of the leadership team for Altus Pharmaceuticals (a spin-out of Vertex Pharmaceuticals and 2006 IPO), where he held several senior management positions. Prior to Altus, he was Director of Sales Operations (The Americas) for Genencor International (2000 IPO; now owned by DuPont), where he led a 40-member commercial team generating over $130 million annually. Earlier in his career, he held business unit and sales management positions with Akzo Nobel of the Netherlands and DuPont/Conoco Chemicals. He has an M.B.A and B.S. degree from Miami University.

Michel Baudry, Ph.D.

Founder & Scientific Advisor

Learn more about Dr. Baudry

Dr. Baudry is an internationally known neuroscientist with over 400 publications and is one of the 100 most cited neuroscientists in the world. He is a professor at Western University of Health Sciences and former professor of biological sciences, neurology and biomedical engineering at University of Southern California in Los Angeles. Dr. Baudry graduated from Ecole Polytechnique in Paris and earned a PhD in biochemistry at University of Paris VII under the direction of professors J.C. Schwartz and J.P. Changeux, two of France’s most distinguished neurobiologists.

Michael Palfreyman, DSc., Ph.D.

SVP Drug Development

Learn more about Dr. Palfreyman

Dr. Palfreyman is an internationally recognized leader in neurological drug development with a successful scientific and business career spanning 35 years. He brings to NeurAegis a distinguished track record of successful drug development and considerable expertise in CNS pharmacology, pharmacogenomics and rational drug design. Dr. Palfreyman’s broad perspective on drug development derives from his experience as Chief Scientific Officer for Amorsa Therapeutics and President and CSO of Psychiatric Genomics; Senior Scientific Advisor to EnVivo Pharmaceuticals and Vitruvean; co-founder of NOVACE; Senior VP for Research and Development at Anadys (formerly Scriptgen); as well as senior executive and scientific leadership roles at Marion Merrell Dow (Sanofi-Aventis) and Beecham (GlaxoSmithKline). In these roles, he successfully developed and demonstrated clinical efficacy of several candidates across multiple therapeutic areas. Dr. Palfreyman holds Ph.D. and D.Sc. degrees and is a member of the Royal Pharmaceutical Society. He continues to be an active scientific contributor with more than 150 publications and 35 issued patents.

Scientific Advisors

Imad Najm, M.D.

Cleveland Clinic

Learn more about Dr. Najm

Imad Michel Najm, MD, is Director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute. Dr. Najm received his medical doctor degree from Saint Joseph University in Beirut, Lebanon, in 1988. Dr. Najm completed his residency in adult neurology at Cleveland Clinic in 1996, and a fellowship in clinical neurophysiology and epilepsy at Cleveland Clinic in 1997. Dr. Najm received his board certification in adult neurology from the American Board of Psychiatry and Neurology in 1998, with an added qualification in clinical neurophysiology in 1999. Between 2000 and 2003, Dr. Najm served as the director of the Epilepsy and Clinical Neurophysiology Fellowship Program at Cleveland Clinic. In 2003, he became the Head of the Section of Adult Epilepsy within the Department of Neurology at Cleveland Clinic, and in 2006, he assumed his current position as the Director of the Cleveland Clinic Epilepsy Center. Dr. Najm has more than 22 years of experience in clinical and basic mechanisms of epilepsy. This includes conducting numerous research projects dedicated to exploring the topic of mechanisms of epilepsy and malformations of cortical dysplasia.